Latest Content

Dr. Priscilla Merriam discusses why sarcoma is often mistaken for a benign growth, how treatment differs across more than 150 types and where patients can find expert care.

The FDA granted accelerated approval to Zenbexus with daratumumab and hyaluronidase-fihj and dexamethasone for previously treated multiple myeloma.

Sixteen years after my own cancer journey, I find myself reflecting on the lasting shadows of cancer and the connection survivors can offer one another.

Genomic testing can show whether a targeted treatment may be an option. In a Medicare study, fewer than 1 in 5 patients with cancer received it in 2023.

Black women with ovarian cancer had a 45% higher risk of death than White women, with the gap widest in high-vulnerability neighborhoods.

Krystal Player-Jackson, oncology nurse of Ochsner LSU Shreveport, continued caring for cancer patients with compassion and resilience even while losing her father and brother to cancer weeks apart.

Nicole Schulz was 14 when she received an AML diagnosis. She shares what carried her through two transplants and 11 months in the hospital.

Adding sirexatamab did not delay cancer growth overall, but patients with higher levels of a blood protein called DKK1 went longer without their cancer worsening.

Laura Yeager reflects on attending a Bridgerton-themed gala as a flat-chested breast cancer survivor, finding humor and freedom in a room full of corsets and cleavage.

Weekly smartphone check-ins that alerted the care team when symptoms worsened and improved physical functioning at six months.

Divesiran met the primary end point of the phase 2 SANRECO trial, with 88% of patients avoiding phlebotomy and keeping hematocrit below 45%, according to new trial results.

Doctors say patients with cancer face distinct risks during the cyclosporiasis outbreak that spans 45 states.

After moving two hours away, a survivor weighs staying with the cancer center that knows her history against finding an oncologist close to home.